Skip to main content

KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.

Publication ,  Journal Article
Burge, RA; Le Roux, O; Popow, O; Spadafora, VK; Rajesh, C; Adair, SJ; Bialousow, L; Murphy, C; Saberi, S; Vaena, SG; Taquey, MC; Allen, S ...
Published in: Cancer Res
January 20, 2026

Patients with pancreatic ductal adenocarcinoma (PDAC) harboring KRASG12R mutations have increased overall survival relative to patients with KRASG12D/V mutations. To investigate the mechanisms underlying this differential outcome, we developed a genetically engineered mouse model (GEMM) harboring KRASG12R and p53R172H mutations (KrasLSL-G12R/+;Trp53LSL-R172H/+;p48Cre-ERTM). Unlike KRASG12D models, KRASG12R-GEMMs exhibited limited tumorigenesis, with only 10% developing pancreatic tumors after one year. Additionally, mice harboring whole-body expression of KRASG12R remained healthy for over one year, whereas KRASG12D mice developed rapid multifocal disease. Comparison of KRAS mutant-selective transcription and signaling in murine and human PDAC cell lines, GEMMs, and patient-derived xenograft mouse models revealed that direct KRAS-mediated PI3K activation is necessary for robust tumor initiation in GEMMs. Unexpectedly, KRAS was not the primary driver of PI3K activity in human PDAC cell lines and patient-derived xenograft models regardless of KRAS mutation. KRASG12R and KRASG12D activated a similar pancreas-specific transcriptional network, but KRASG12R promoted these pathways less robustly due to limited ERK/MAPK nuclear translocation. Finally, KRASG12R human pancreatic tumors had an altered tumor microenvironment (TME) with reduced collagen deposition and metastatic liver invasion. Together, this study demonstrated that KRASG12R is capable of driving tumorigenesis despite the reduced ERK/MAPK nuclear translocation and transcriptional output. Although human KRASG12D and KRASG12R-mutant tumors display unexpected similarities in PI3K activity, the differential ERK/MAPK signaling activity and the extrinsic consequences on the TME provide support for using KRASG12R mutation status as a prognostic biomarker for therapeutic strategies.

Duke Scholars

Published In

Cancer Res

DOI

EISSN

1538-7445

Publication Date

January 20, 2026

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Burge, R. A., Le Roux, O., Popow, O., Spadafora, V. K., Rajesh, C., Adair, S. J., … Hobbs, G. A. (2026). KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-25-2630
Burge, Rachel A., Ozgun Le Roux, Olesja Popow, Victoria K. Spadafora, Christabelle Rajesh, Sara J. Adair, Lucas Bialousow, et al. “KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.Cancer Res, January 20, 2026. https://doi.org/10.1158/0008-5472.CAN-25-2630.
Burge RA, Le Roux O, Popow O, Spadafora VK, Rajesh C, Adair SJ, et al. KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Cancer Res. 2026 Jan 20;
Burge, Rachel A., et al. “KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment.Cancer Res, Jan. 2026. Pubmed, doi:10.1158/0008-5472.CAN-25-2630.
Burge RA, Le Roux O, Popow O, Spadafora VK, Rajesh C, Adair SJ, Bialousow L, Murphy C, Saberi S, Vaena SG, Taquey MC, Allen S, Han L, Helke KL, Sharma S, Ostrowski MC, Guttridge DC, Dincman TA, Bauer TW, Kashatus DF, McFall T, Haigis KM, Hollingsworth MA, Counter CM, Der CJ, Hobbs GA. KRASG12R-Mutant Pancreatic Cancer Features Limited ERK/MAPK Transcriptional Activity and a Distinctive Tumor Microenvironment. Cancer Res. 2026 Jan 20;

Published In

Cancer Res

DOI

EISSN

1538-7445

Publication Date

January 20, 2026

Location

United States

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 3101 Biochemistry and cell biology
  • 1112 Oncology and Carcinogenesis